Vivimed Labs Limited (NSE:VIVIMEDLAB)

Market Cap	490.85M -42.8%
Revenue (ttm)	883.92M -35.5%
Net Income	-349.49M
EPS	-4.21
Shares Out	82.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,812
Open	5.89
Previous Close	5.98
Day's Range	5.84 - 6.10
52-Week Range	5.15 - 29.40
Beta	0.72
Analysts	Hold
Price Target	142.00 (+2,298.65%)
Earnings Date	May 30, 2026

About Vivimed Labs

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 586
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VIVIMEDLAB

Financial Performance

In fiscal year 2025, Vivimed Labs's revenue was 1.21 billion, a decrease of -24.15% compared to the previous year's 1.59 billion. Losses were -319.61 million, -29.67% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error